BRAF and melanoma: Furthermore, the crosstalk between the Hh pathway and other signaling networks, such as the PI3K/AKT and MAPK pathways, highlights the potential for Itraconazole to synergize with other therapeutic strategies, such as BRAF inhibitors or immune checkpoint inhibitors, to overcome resistance mechanisms in melanoma treatment.